Cargando…

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis

The reactivation of latent Leishmania infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lupia, Tommaso, Corcione, Silvia, Fornari, Valentina, Rizzello, Barbara, Bosio, Roberta, Brusa, Maria Teresa, De Rosa, Francesco Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609957/ https://www.ncbi.nlm.nih.gov/pubmed/36288060 http://dx.doi.org/10.3390/tropicalmed7100319

Ejemplares similares

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
por: van Baarsen, Lisa GM, et al.
Publicado: (2014)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2023)

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies
por: Sánchez-Rodríguez, Guillermo, et al.
Publicado: (2023)

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry
por: Lupia, Tommaso, et al.
Publicado: (2022)

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
por: Blauvelt, Andrew, et al.
Publicado: (2018)

First Human Usutu Virus Reported in Asti (Piedmont, Italy, August 2022) and Early Follow-Up
por: Lupia, Tommaso, et al.
Publicado: (2022)

Dual inhibition of IL-17A and IL-17F in psoriatic disease
por: Iznardo, Helena, et al.
Publicado: (2021)

The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis
por: Vecellio, Matteo, et al.
Publicado: (2021)

Prophylactic interferon-γ and interleukin-17 facilitate parasite clearance in experimental visceral leishmaniasis
por: Kumar, Prabin, et al.
Publicado: (2019)

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
por: Bolt, Janne W., et al.
Publicado: (2022)

The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis
por: Maeda, Shinji, et al.
Publicado: (2012)

CXCL4 is a novel inducer of human Th17 cells and correlates with IL‐17 and IL‐22 in psoriatic arthritis
por: Affandi, Alsya J., et al.
Publicado: (2018)

The effects of IL-17/IL-17R inhibitors on atherosclerosis in psoriasis and psoriatic arthritis: A protocol for systematic review and meta analysis
por: Liu, Ningyuan, et al.
Publicado: (2021)

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
por: McGonagle, Dennis G, et al.
Publicado: (2019)

Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)
por: Lupia, Tommaso, et al.
Publicado: (2022)

Autochthonous West Nile Virus Infection Outbreak in Humans (Asti, Piedmont, Italy, August–October 2018) and Long-Term Sequelae Follow-Up
por: Lupia, Tommaso, et al.
Publicado: (2022)

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
por: Sakkas, Lazaros I., et al.
Publicado: (2019)

New insight into the functions of the interleukin-17 receptor adaptor protein Act1 in psoriatic arthritis
por: Doyle, Matthew S, et al.
Publicado: (2012)

Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
por: Joven, Beatriz, et al.
Publicado: (2023)

SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor
por: Foti, Rosario, et al.
Publicado: (2020)

Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin
por: Venetsanopoulou, Aliki I., et al.
Publicado: (2020)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study
por: Petersen, Magnus B, et al.
Publicado: (2023)

Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis
por: Girbash, Ehab F., et al.
Publicado: (2023)

IL-17A, IL-17RC polymorphisms and IL17 plasma levels in Tunisian patients with rheumatoid arthritis
por: Dhaouadi, Tarak, et al.
Publicado: (2018)

A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile
por: Bautista-Herrera, LA, et al.
Publicado: (2020)

Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
por: Boutet, Marie-Astrid, et al.
Publicado: (2018)

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
por: Glatt, Sophie, et al.
Publicado: (2018)

Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review
por: Wang, Jiao, et al.
Publicado: (2023)

17. Case of multiple insufficiency fractures in a Psoriatic arthritis patient
por: Janakiraman, Geetha Lakshmi, et al.
Publicado: (2017)

Mannan-induced Nos2 in macrophages enhances IL-17–driven psoriatic arthritis by innate lymphocytes
por: Zhong, Jianghong, et al.
Publicado: (2018)

Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link?
por: Zafiriou, Efterpi, et al.
Publicado: (2021)

Th17 and Th22 cells in psoriatic arthritis and psoriasis
por: Benham, Helen, et al.
Publicado: (2013)

IL17A and IL17F gene polymorphisms in patients with rheumatoid arthritis
por: Pawlik, Andrzej, et al.
Publicado: (2016)

Interleukin-17A (IL-17A): A silent amplifier of COVID-19
por: Maione, Francesco, et al.
Publicado: (2021)

IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
por: Noordenbos, Troy, et al.
Publicado: (2011)

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
por: Pelechas, Eleftherios, et al.
Publicado: (2017)

Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis
por: Sarkar, S, et al.
Publicado: (2014)

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
por: Tsiogka, Aikaterini, et al.
Publicado: (2023)

Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A
por: Hartley, Mary-Anne, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7qhm54mkudq250gm1mkrfl4o3h